The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
Phase 2
Active, not recruiting
NCT03414658
| Condition | Breast Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Adrienne G. Waks |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 100 participants |
|---|
| Interventions | Vinorelbine, Trastuzumab, Avelumab, Utomilumab |
|---|
| Start date | Jun 21, 2018 |
|---|
| Completion date | May 1, 2023 |
|---|
| Results posted | Apr 18, 2024 |
|---|
Summary
This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: * Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) * Group B: Trastuzumab + Vinorelbine + Avelumab * Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)
Progression Free Survival
2 years · months
| NH: Trastuzumab + Vinorelbine | 2 months |
|---|
| NHA: Trastuzumab + Vinorelbine + Avelumab | 3.8 months |
|---|
| NHAU: Trastuzumab + Vinorelbine + Avelumab + Utomilumab | 4.9 months |
|---|
| p-value | 0.025 |
|---|
| Hazard Ratio (HR) | 0.53 (95% CI 0.35–0.81) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.